Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Guardant Health, Inc. - Common Stock (NQ:GH)

46.21 -0.25 (-0.54%)
Streaming Delayed Price Updated: 12:35 PM EDT, Jul 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Guardant Health, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Cathie Wood's Ark Invest Offloads Meta, Loads Up On Teradyne, Caris Life Sciences
Ark Invest made significant trades in TER, META, CAI, and GH. Wood's emphasis on AI's impact on jobs aligns with their purchases and sales. 
Via Benzinga
Topics Artificial Intelligence
First Patient Enrolled in National Cancer Institute’s Vanguard Study Evaluating Guardant Health’s Shield Multi-Cancer Detection Test
From Guardant Health, Inc.
Via Business Wire
Guardant Health to Report Second Quarter 2025 Financial Results on July 30, 2025
From Guardant Health, Inc.
Via Business Wire
Guardant Health, Gilead Sciences, Inspire Medical Systems, Enovis, and AMN Healthcare Services Stocks Trade Down, What You Need To Know
A number of stocks fell in the afternoon session after the U.S. administration announced a sharp escalation in trade tensions by threatening new tariffs on Canada. 
Via StockStory
Topics ETFs Stocks World Trade
Could Personalized Medicine Be Your Portfolio's Next Big Winner? Find Out
BofA analysts review the promise and limits of AI in precision medicine, highlighting key players like Tempus, Guardant, and Exact Sciences. 
Via Benzinga
Topics Artificial Intelligence
3 Cash-Burning Stocks Facing Headwinds
While some companies burn cash to fuel expansion, others struggle to turn spending into sustainable growth. A high cash burn rate without a strong balance sheet can leave investors exposed to... 
Via StockStory
3 of Wall Street’s Favorite Stocks Facing Headwinds
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings,... 
Via StockStory
2 Mooning Stocks Worth Your Attention and 1 to Be Wary Of
The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial... 
Via StockStory
Guardant Health Wins Fast Company’s 2025 World Changing Ideas Award for Shield Blood Test for Colorectal Cancer Screening
From Guardant Health, Inc.
Via Business Wire
New Study Published in ESMO Open Highlights Guardant Reveal's Performance in Detecting Minimal Residual Disease in Patients with Early-Stage Breast Cancer
From Guardant Health, Inc.
Via Business Wire
Cathie Wood's ARK Invest Buys More Amazon Stock: Retail Still On The Sidelines
The widely watched investor also bought AMD and Guardant Health stocks, while cutting its stakes in CoreWeave and Palantir. 
Via Stocktwits
Topics ETFs World Trade
Why Guardant Health Stock Surged Nearly 9% Higher Today
Via The Motley Fool
Why Is Cancer Diagnostic Guardant Health Stock Trading Higher On Tuesday?
Guardant Health's Shield test receives FDA breakthrough status and NCCN guideline inclusion, with high accuracy shown in new ASCO and ECLIPSE study data. 
Via Benzinga
Signet Posts Upbeat Earnings, Joins Ferguson Enterprises, Dollar General And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
FDA Grants Breakthrough Device Designation to Guardant Health’s Shield Multi-Cancer Detection (MCD) Test
From Guardant Health, Inc.
Via Business Wire
National Comprehensive Cancer Network (NCCN) Updates Colorectal Cancer Screening Guidelines to Include Shield Blood-Based Screening
From Guardant Health, Inc.
Via Business Wire
SERENA-6 Phase III Trial Demonstrates Clinical Value of Guardant360 CDx Test to Detect Emergence of Endocrine Resistance and Inform a Switch in Therapy Before Radiological Disease Progression in Advanced Breast Cancer
From Guardant Health, Inc.
Via Business Wire
In Largest Molecular Residual Disease (MRD) Study in Colon Cancer, Guardant Reveal Testing Prior to Chemotherapy Provides Robust Stratification for Risk of Disease Recurrence and Survival to Enable Timely Treatment Decisions
From Guardant Health, Inc.
Via Business Wire
2 Growth Stocks with Impressive Fundamentals and 1 to Question
Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 will surely remember that the market’s... 
Via StockStory
Firing on All Cylinders: Guardant Health (NASDAQ:GH) Q1 Earnings Lead the Way
As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the testing & diagnostics services industry, including Guardant Health (NASDAQ:GH) and... 
Via StockStory
Guardant Health Introduces Nearly a Dozen Groundbreaking Smart Liquid Biopsy Applications for Guardant360 Liquid Test
From Guardant Health, Inc.
Via Business Wire
Guardant Health and Collaborators to Present Over 19 Studies Demonstrating Role of Liquid Biopsy in Advancing Precision Oncology at 2025 ASCO Annual Meeting
From Guardant Health, Inc.
Via Business Wire
Guardant Health, Evolent Health, Charles River Laboratories, Avantor, and Lumen Stocks Trade Down, What You Need To Know
A number of stocks fell in the afternoon session after the major indices pulled back (Nasdaq -1.3%, S&P 500 - 1.4%) as Treasury yields rose, reflecting market anxiety over a draft federal budget that... 
Via StockStory
Topics Bonds Stocks
Guardant Health Introduces Comprehensive Immunohistochemistry Testing for Solid Tumors
From Guardant Health, Inc.
Via Business Wire
Guardant Health Introduces Hereditary Cancer Testing to Identify Inherited Predispositions to Certain Types of Cancer
From Guardant Health, Inc.
Via Business Wire
Guardant Health: A Promising Player in the Liquid Biopsy Market
Via The Motley Fool
GH Q1 Earnings Call: Guardant Health Lifts Full-Year Guidance Following Oncology and Screening Momentum
Diagnostics company Guardant Health (NASDAQ:GH) announced better-than-expected revenue in Q1 CY2025, with sales up 20.8% year on year to $203.5 million. The company’s full-year revenue guidance of $885... 
Via StockStory
2 Volatile Stocks Worth Investigating and 1 to Steer Clear Of
Market swings can be tough to stomach, and volatile stocks often experience exaggerated moves in both directions. While many thrive during risk-on environments, many also struggle to maintain investor... 
Via StockStory
Topics Stocks
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Guardant Health to Participate in Upcoming Investor Conferences
From Guardant Health, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.